ID   TIF1B_HUMAN             Reviewed;         835 AA.
AC   Q13263; O00677; Q7Z632; Q93040; Q96IM1;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 5.
DT   12-OCT-2022, entry version 252.
DE   RecName: Full=Transcription intermediary factor 1-beta {ECO:0000305};
DE            Short=TIF1-beta;
DE   AltName: Full=E3 SUMO-protein ligase TRIM28;
DE            EC=2.3.2.27;
DE   AltName: Full=KRAB-associated protein 1;
DE            Short=KAP-1;
DE   AltName: Full=KRAB-interacting protein 1;
DE            Short=KRIP-1;
DE   AltName: Full=Nuclear corepressor KAP-1;
DE   AltName: Full=RING finger protein 96;
DE   AltName: Full=RING-type E3 ubiquitin transferase TIF1-beta {ECO:0000305};
DE   AltName: Full=Tripartite motif-containing protein 28;
GN   Name=TRIM28 {ECO:0000312|HGNC:HGNC:16384};
GN   Synonyms=KAP1, RNF96, TIF1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=8769649; DOI=10.1101/gad.10.16.2067;
RA   Friedman J.R., Fredericks W.J., Jensen D.E., Speicher D.W., Huang X.-P.,
RA   Neilson E.G., Rauscher F.J. III;
RT   "KAP-1, a novel corepressor for the highly conserved KRAB repression
RT   domain.";
RL   Genes Dev. 10:2067-2078(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION,
RP   TISSUE SPECIFICITY, AND INTERACTION WITH ZNF10.
RX   PubMed=9016654; DOI=10.1093/nar/24.24.4859;
RA   Moosmann P.R., Georgiev O., le Douarin B., Bourquin J.-P., Schaffner W.;
RT   "Transcriptional repression by RING finger protein TIF1 beta that interacts
RT   with the KRAB repressor domain of KOX1.";
RL   Nucleic Acids Res. 24:4859-4867(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Spleen;
RA   Emison E.S., Lewis B.C., Shim H., Li Q., Dang C.V., Lee L.A.;
RL   Submitted (MAR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Skin, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-30, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT
RP   ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=T-cell;
RA   Bienvenut W.V., Kanor S., Tissot J.-D., Quadroni M.;
RL   Submitted (MAY-2006) to UniProtKB.
RN   [6]
RP   PROTEIN SEQUENCE OF 2-32; 408-427 AND 493-507, CLEAVAGE OF INITIATOR
RP   METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Ovarian carcinoma;
RA   Bienvenut W.V.;
RL   Submitted (JAN-2010) to UniProtKB.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 486-835.
RA   Lyle R., Hewitt J.E.;
RL   Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PROTEIN SEQUENCE OF N-TERMINUS, OLIGOMERIZATION, INTERACTION WITH THE KRAB
RP   DOMAIN, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17512541; DOI=10.1016/j.jmb.2007.03.047;
RA   Peng H., Gibson L.C., Capili A.D., Borden K.L., Osborne M.J., Harper S.L.,
RA   Speicher D.W., Zhao K., Marmorstein R., Rock T.A., Rauscher F.J. III;
RT   "The structurally disordered KRAB repression domain is incorporated into a
RT   protease resistant core upon binding to KAP-1-RBCC domain.";
RL   J. Mol. Biol. 370:269-289(2007).
RN   [9]
RP   INTERACTION WITH CBX1; CBX3 AND CBX5, AND SUBCELLULAR LOCATION.
RX   PubMed=10330177; DOI=10.1128/mcb.19.6.4366;
RA   Ryan R.F., Schultz D.C., Ayyanathan K., Singh P.B., Friedman J.R.,
RA   Fredericks W.J., Rauscher F.J. III;
RT   "KAP-1 corepressor protein interacts and colocalizes with heterochromatic
RT   and euchromatic HP1 proteins: a potential role for Kruppel-associated box-
RT   zinc finger proteins in heterochromatin-mediated gene silencing.";
RL   Mol. Cell. Biol. 19:4366-4378(1999).
RN   [10]
RP   INTERACTION WITH ZFP53 AND ZFP68, AND FUNCTION.
RX   PubMed=10347202; DOI=10.1074/jbc.274.23.16412;
RA   Agata Y., Matsuda E., Shimizu A.;
RT   "Two novel Kruppel-associated box-containing zinc-finger proteins, KRAZ1
RT   and KRAZ2, repress transcription through functional interaction with the
RT   corepressor KAP-1 (TIF1beta/KRIP-1).";
RL   J. Biol. Chem. 274:16412-16422(1999).
RN   [11]
RP   INTERACTION WITH NCOR1.
RX   PubMed=11013263; DOI=10.1074/jbc.m007864200;
RA   Underhill C., Qutob M.S., Yee S.P., Torchia J.;
RT   "A novel nuclear receptor corepressor complex, N-CoR, contains components
RT   of the mammalian SWI/SNF complex and the corepressor KAP-1.";
RL   J. Biol. Chem. 275:40463-40470(2000).
RN   [12]
RP   INTERACTION WITH CHD3.
RX   PubMed=11230151; DOI=10.1101/gad.869501;
RA   Schultz D.C., Friedman J.R., Rauscher F.J. III;
RT   "Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the
RT   PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel
RT   isoform of the Mi-2alpha subunit of NuRD.";
RL   Genes Dev. 15:428-443(2001).
RN   [13]
RP   INTERACTION WITH SETDB1, AND FUNCTION.
RX   PubMed=11959841; DOI=10.1101/gad.973302;
RA   Schultz D.C., Ayyanathan K., Negorev D., Maul G.G., Rauscher F.J. III;
RT   "SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific
RT   methyltransferase that contributes to HP1-mediated silencing of euchromatic
RT   genes by KRAB zinc-finger proteins.";
RL   Genes Dev. 16:919-932(2002).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [15]
RP   INTERACTION WITH CBX5, AND FUNCTION.
RX   PubMed=15882967; DOI=10.1016/j.bbrc.2005.04.016;
RA   Lechner M.S., Schultz D.C., Negorev D., Maul G.G., Rauscher F.J. III;
RT   "The mammalian heterochromatin protein 1 binds diverse nuclear proteins
RT   through a common motif that targets the chromoshadow domain.";
RL   Biochem. Biophys. Res. Commun. 331:929-937(2005).
RN   [16]
RP   INTERACTION WITH MDM2, AND FUNCTION.
RX   PubMed=16107876; DOI=10.1038/sj.emboj.7600791;
RA   Wang C., Ivanov A., Chen L., Fredericks W.J., Seto E., Rauscher F.J. III,
RA   Chen J.;
RT   "MDM2 interaction with nuclear corepressor KAP1 contributes to p53
RT   inactivation.";
RL   EMBO J. 24:3279-3290(2005).
RN   [17]
RP   INTERACTION WITH MDM2 IN THE TRIM28/KAP1-MDM2-P53/TP53 COMPLEX.
RX   PubMed=17056014; DOI=10.1016/j.bbrc.2006.10.022;
RA   Okamoto K., Kitabayashi I., Taya Y.;
RT   "KAP1 dictates p53 response induced by chemotherapeutic agents via Mdm2
RT   interaction.";
RL   Biochem. Biophys. Res. Commun. 351:216-222(2006).
RN   [18]
RP   INTERACTION WITH FES/FPS, AND PHOSPHORYLATION.
RX   PubMed=16792528; DOI=10.1042/bj20060194;
RA   Delfino F.J., Shaffer J.M., Smithgall T.E.;
RT   "The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner,
RT   substrate and activator of the c-Fes protein tyrosine kinase.";
RL   Biochem. J. 399:141-150(2006).
RN   [19]
RP   PHOSPHORYLATION AT SER-824, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17178852; DOI=10.1158/0008-5472.can-06-4138;
RA   White D.E., Negorev D., Peng H., Ivanov A.V., Maul G.G., Rauscher F.J. III;
RT   "KAP1, a novel substrate for PIKK family members, colocalizes with numerous
RT   damage response factors at DNA lesions.";
RL   Cancer Res. 66:11594-11599(2006).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-473, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-473; THR-541 AND SER-757, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [22]
RP   PHOSPHORYLATION AT SER-824, AND FUNCTION.
RX   PubMed=16862143; DOI=10.1038/ncb1446;
RA   Ziv Y., Bielopolski D., Galanty Y., Lukas C., Taya Y., Schultz D.C.,
RA   Lukas J., Bekker-Jensen S., Bartek J., Shiloh Y.;
RT   "Chromatin relaxation in response to DNA double-strand breaks is modulated
RT   by a novel ATM- and KAP-1 dependent pathway.";
RL   Nat. Cell Biol. 8:870-876(2006).
RN   [23]
RP   INTERACTION WITH MAGEC2.
RX   PubMed=17942928; DOI=10.1158/0008-5472.can-07-1478;
RA   Yang B., O'Herrin S.M., Wu J., Reagan-Shaw S., Ma Y., Bhat K.M.,
RA   Gravekamp C., Setaluri V., Peters N., Hoffmann F.M., Peng H., Ivanov A.V.,
RA   Simpson A.J., Longley B.J.;
RT   "MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress
RT   p53-dependent apoptosis in MAGE-positive cell lines.";
RL   Cancer Res. 67:9954-9962(2007).
RN   [24]
RP   INTERACTION WITH ZNF350, SUMOYLATION AT LYS-554; LYS-779 AND LYS-804,
RP   FUNCTION, AND MUTAGENESIS OF LYS-554; LYS-575; LYS-676; LYS-779 AND
RP   LYS-804.
RX   PubMed=17079232; DOI=10.1074/jbc.m606306200;
RA   Lee Y.K., Thomas S.N., Yang A.J., Ann D.K.;
RT   "Doxorubicin down-regulates Kruppel-associated box domain-associated
RT   protein 1 sumoylation that relieves its transcription repression on
RT   p21WAF1/CIP1 in breast cancer MCF-7 cells.";
RL   J. Biol. Chem. 282:1595-1606(2007).
RN   [25]
RP   INTERACTION WITH E2F1, AND FUNCTION.
RX   PubMed=17704056; DOI=10.1074/jbc.m704757200;
RA   Wang C., Rauscher F.J. III, Cress W.D., Chen J.;
RT   "Regulation of E2F1 function by the nuclear corepressor KAP1.";
RL   J. Biol. Chem. 282:29902-29909(2007).
RN   [26]
RP   PHOSPHORYLATION AT SER-824, SUMOYLATION, FUNCTION, AND MUTAGENESIS OF
RP   LEU-306; LYS-554; LYS-779; LYS-804 AND SER-824.
RX   PubMed=17942393; DOI=10.1074/jbc.m706912200;
RA   Li X., Lee Y.K., Jeng J.C., Yen Y., Schultz D.C., Shih H.M., Ann D.K.;
RT   "Role for KAP1 serine 824 phosphorylation and sumoylation/desumoylation
RT   switch in regulating KAP1-mediated transcriptional repression.";
RL   J. Biol. Chem. 282:36177-36189(2007).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17924679; DOI=10.1021/pr070152u;
RA   Yu L.R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.;
RT   "Improved titanium dioxide enrichment of phosphopeptides from HeLa cells
RT   and high confident phosphopeptide identification by cross-validation of
RT   MS/MS and MS/MS/MS spectra.";
RL   J. Proteome Res. 6:4150-4162(2007).
RN   [28]
RP   SUMOYLATION AT LYS-750, FUNCTION, DOMAIN PHD-TYPE, INTERACTION WITH CHD3
RP   AND SETDB1, AND MUTAGENESIS OF LYS-554; LYS-575; CYS-651; LYS-676; LYS-750;
RP   LYS-779 AND LYS-804.
RX   PubMed=18082607; DOI=10.1016/j.molcel.2007.11.012;
RA   Ivanov A.V., Peng H., Yurchenko V., Yap K.L., Negorev D.G., Schultz D.C.,
RA   Psulkowski E., Fredericks W.J., White D.E., Maul G.G., Sadofsky M.J.,
RA   Zhou M.M., Rauscher F.J. III;
RT   "PHD domain-mediated E3 ligase activity directs intramolecular sumoylation
RT   of an adjacent bromodomain required for gene silencing.";
RL   Mol. Cell 28:823-837(2007).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-501, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [30]
RP   INTERACTION WITH ZNF256, AND FUNCTION.
RX   PubMed=18060868; DOI=10.1016/j.bbrc.2007.11.118;
RA   Suzuki C., Murakumo Y., Kawase Y., Sato T., Morinaga T., Fukuda N.,
RA   Enomoto A., Ichihara M., Takahashi M.;
RT   "A novel GDNF-inducible gene, BMZF3, encodes a transcriptional repressor
RT   associated with KAP-1.";
RL   Biochem. Biophys. Res. Commun. 366:226-232(2008).
RN   [31]
RP   INTERACTION WITH SMARCAD1.
RX   PubMed=18675275; DOI=10.1016/j.jmb.2008.07.031;
RA   Okazaki N., Ikeda S., Ohara R., Shimada K., Yanagawa T., Nagase T.,
RA   Ohara O., Koga H.;
RT   "The novel protein complex with SMARCAD1/KIAA1122 binds to the vicinity of
RT   TSS.";
RL   J. Mol. Biol. 382:257-265(2008).
RN   [32]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=T-cell;
RX   PubMed=19367720; DOI=10.1021/pr800500r;
RA   Carrascal M., Ovelleiro D., Casas V., Gay M., Abian J.;
RT   "Phosphorylation analysis of primary human T lymphocytes using sequential
RT   IMAC and titanium oxide enrichment.";
RL   J. Proteome Res. 7:5167-5176(2008).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; SER-439; SER-471;
RP   SER-473; SER-489; SER-752 AND SER-757, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [36]
RP   INTERACTION WITH RRP1B.
RX   PubMed=19710015; DOI=10.1074/jbc.m109.023457;
RA   Crawford N.P., Yang H., Mattaini K.R., Hunter K.W.;
RT   "The metastasis efficiency modifier ribosomal RNA processing 1 homolog B
RT   (RRP1B) is a chromatin-associated factor.";
RL   J. Biol. Chem. 284:28660-28673(2009).
RN   [37]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-473; SER-501 AND SER-594, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-304; LYS-340; LYS-377; LYS-770
RP   AND LYS-774, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [39]
RP   SUMOYLATION AT LYS-779.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20388717; DOI=10.1074/jbc.m110.106955;
RA   Blomster H.A., Imanishi S.Y., Siimes J., Kastu J., Morrice N.A.,
RA   Eriksson J.E., Sistonen L.;
RT   "In vivo identification of sumoylation sites by a signature tag and
RT   cysteine-targeted affinity purification.";
RL   J. Biol. Chem. 285:19324-19329(2010).
RN   [40]
RP   INTERACTION WITH ERBB4 AND MDM2 IN THE TRIM28/KAP1-ERBB4-MDM2 COMPLEX AND
RP   WITH MDM2 AND P53/TP53 IN THE TRIM28/KAP1-MDM2-P53/TP53 COMPLEX, FUNCTION,
RP   SUBCELLULAR LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=20858735; DOI=10.1158/1541-7786.mcr-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage
RT   response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [41]
RP   FUNCTION, UBIQUITINATION, AND INTERACTION WITH MAGEC2.
RX   PubMed=20864041; DOI=10.1016/j.molcel.2010.08.029;
RA   Doyle J.M., Gao J., Wang J., Yang M., Potts P.R.;
RT   "MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases.";
RL   Mol. Cell 39:963-974(2010).
RN   [42]
RP   INTERACTION WITH CBX5 AND POGZ, AND MUTAGENESIS OF VAL-488 AND LEU-490.
RX   PubMed=20562864; DOI=10.1038/ncb2075;
RA   Nozawa R.S., Nagao K., Masuda H.T., Iwasaki O., Hirota T., Nozaki N.,
RA   Kimura H., Obuse C.;
RT   "Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms
RT   through Aurora B activation.";
RL   Nat. Cell Biol. 12:719-727(2010).
RN   [43]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-19; SER-473; SER-489; THR-541; SER-697; SER-752 AND
RP   SER-757, CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [44]
RP   PHOSPHORYLATION AT SER-824, SUMOYLATION, FUNCTION, INTERACTION WITH PPP1CA
RP   AND PPP1CB, AND MUTAGENESIS OF LYS-366; ILE-368; PHE-370; SER-440; SER-501
RP   AND SER-824.
RX   PubMed=20424263; DOI=10.1126/scisignal.2000781;
RA   Li X., Lin H.H., Chen H., Xu X., Shih H.M., Ann D.K.;
RT   "SUMOylation of the transcriptional co-repressor KAP1 is regulated by the
RT   serine and threonine phosphatase PP1.";
RL   Sci. Signal. 3:RA32-RA32(2010).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [46]
RP   FUNCTION AS SUMO LIGASE, AND INTERACTION WITH IRF7.
RX   PubMed=21940674; DOI=10.4049/jimmunol.1101704;
RA   Liang Q., Deng H., Li X., Wu X., Tang Q., Chang T.H., Peng H.,
RA   Rauscher F.J. III, Ozato K., Zhu F.;
RT   "Tripartite motif-containing protein 28 is a small ubiquitin-related
RT   modifier E3 ligase and negative regulator of IFN regulatory factor 7.";
RL   J. Immunol. 187:4754-4763(2011).
RN   [47]
RP   IDENTIFICATION IN A COMPLEX WITH EHMT2; HDAC1 AND HDAC2.
RX   PubMed=21549307; DOI=10.1016/j.molcel.2011.02.036;
RA   Rowbotham S.P., Barki L., Neves-Costa A., Santos F., Dean W., Hawkes N.,
RA   Choudhary P., Will W.R., Webster J., Oxley D., Green C.M., Varga-Weisz P.,
RA   Mermoud J.E.;
RT   "Maintenance of silent chromatin through replication requires SWI/SNF-like
RT   chromatin remodeler SMARCAD1.";
RL   Mol. Cell 42:285-296(2011).
RN   [48]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, PHOSPHORYLATION [LARGE SCALE
RP   ANALYSIS] AT SER-19; SER-473; SER-479 AND SER-683, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [49]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [50]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [51]
RP   FUNCTION, INTERACTION WITH ZNF268; KOX1 AND ZNF300, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF CYS-65 AND CYS-68.
RX   PubMed=23665872; DOI=10.1007/s00018-013-1359-4;
RA   Wang W., Cai J., Wu Y., Hu L., Chen Z., Hu J., Chen Z., Li W., Guo M.,
RA   Huang Z.;
RT   "Novel activity of KRAB domain that functions to reinforce nuclear
RT   localization of KRAB-containing zinc finger proteins by interacting with
RT   KAP1.";
RL   Cell. Mol. Life Sci. 70:3947-3958(2013).
RN   [52]
RP   FUNCTION, AND INTERACTION WITH ZFP90.
RX   PubMed=23543754; DOI=10.4049/jimmunol.1203561;
RA   Huang C., Martin S., Pfleger C., Du J., Buckner J.H., Bluestone J.A.,
RA   Riley J.L., Ziegler S.F.;
RT   "Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to
RT   a chromatin-remodeling complex that contains KAP1/TRIM28.";
RL   J. Immunol. 190:4470-4473(2013).
RN   [53]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-26; SER-138; SER-417;
RP   SER-453; SER-473; SER-479; SER-489; THR-498; SER-501; THR-541; SER-752;
RP   SER-757 AND SER-784, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [54]
RP   INTERACTION WITH SETX.
RX   PubMed=23149945; DOI=10.1128/mcb.01195-12;
RA   Yuce O., West S.C.;
RT   "Senataxin, defective in the neurodegenerative disorder ataxia with
RT   oculomotor apraxia 2, lies at the interface of transcription and the DNA
RT   damage response.";
RL   Mol. Cell. Biol. 33:406-417(2013).
RN   [55]
RP   FUNCTION, POSSIBLE IDENTIFICATION IN A COREPRESSOR COMPLEX, AND
RP   CHROMATIN-BINDING.
RX   PubMed=24623306; DOI=10.7554/elife.02313;
RA   Serra R.W., Fang M., Park S.M., Hutchinson L., Green M.R.;
RT   "A KRAS-directed transcriptional silencing pathway that mediates the CpG
RT   island methylator phenotype.";
RL   Elife 3:E02313-E02313(2014).
RN   [56]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-19; SER-501; THR-541;
RP   SER-594; SER-683 AND SER-689, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [57]
RP   INTERACTION WITH HERPES VIRUS 8 PROTEIN LANA1 (MICROBIAL INFECTION),
RP   FUNCTION (MICROBIAL INFECTION), AND SUBCELLULAR LOCATION.
RX   PubMed=24741090; DOI=10.1128/jvi.00596-14;
RA   Sun R., Liang D., Gao Y., Lan K.;
RT   "Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host
RT   KAP1 to facilitate establishment of viral latency.";
RL   J. Virol. 88:7331-7344(2014).
RN   [58]
RP   INTERACTION WITH ZBTB1.
RX   PubMed=24657165; DOI=10.1016/j.molcel.2014.02.017;
RA   Kim H., Dejsuphong D., Adelmant G., Ceccaldi R., Yang K., Marto J.A.,
RA   D'Andrea A.D.;
RT   "Transcriptional repressor ZBTB1 promotes chromatin remodeling and
RT   translesion DNA synthesis.";
RL   Mol. Cell 54:107-118(2014).
RN   [59]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-31; LYS-199; LYS-254; LYS-261;
RP   LYS-319; LYS-366; LYS-377; LYS-434; LYS-469; LYS-575; LYS-750; LYS-770;
RP   LYS-774 AND LYS-779, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [60]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-377; LYS-469; LYS-750 AND
RP   LYS-779, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [61]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-31; LYS-377; LYS-469; LYS-750;
RP   LYS-779 AND LYS-804, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [62]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-377; LYS-750 AND LYS-779, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [63]
RP   FUNCTION, INTERACTION WITH ATRX, AND FORMATION OF A COMPLEX WITH ATRX;
RP   SETDB1 AND ZNF274.
RX   PubMed=27029610; DOI=10.1080/15592294.2016.1169351;
RA   Valle-Garcia D., Qadeer Z.A., McHugh D.S., Ghiraldini F.G., Chowdhury A.H.,
RA   Hasson D., Dyer M.A., Recillas-Targa F., Bernstein E.;
RT   "ATRX binds to atypical chromatin domains at the 3' exons of zinc finger
RT   genes to preserve H3K9me3 enrichment.";
RL   Epigenetics 11:398-414(2016).
RN   [64]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-31; LYS-127; LYS-199; LYS-254;
RP   LYS-261; LYS-272; LYS-304; LYS-319; LYS-377; LYS-407; LYS-434; LYS-469;
RP   LYS-507; LYS-554; LYS-750; LYS-770; LYS-774; LYS-779 AND LYS-804, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [65]
RP   INTERACTION WITH ZNF746.
RX   PubMed=31856708; DOI=10.1186/s12860-019-0243-y;
RA   Al Chiblak M., Steinbeck F., Thiesen H.J., Lorenz P.;
RT   "DUF3669, a 'domain of unknown function' within ZNF746 and ZNF777,
RT   oligomerizes and contributes to transcriptional repression.";
RL   BMC Mol. Cell Biol. 20:60-60(2019).
RN   [66]
RP   INTERACTION WITH TRIM17.
RX   PubMed=30042493; DOI=10.1038/s41418-018-0169-5;
RA   Lionnard L., Duc P., Brennan M.S., Kueh A.J., Pal M., Guardia F., Mojsa B.,
RA   Damiano M.A., Mora S., Lassot I., Ravichandran R., Cochet C.,
RA   Aouacheria A., Potts P.R., Herold M.J., Desagher S., Kucharczak J.;
RT   "TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-
RT   apoptotic activity of BCL2A1.";
RL   Cell Death Differ. 26:902-917(2019).
RN   [67]
RP   INTERACTION WITH ZNF263.
RX   PubMed=32051553; DOI=10.1038/s41388-020-1206-7;
RA   Yu Z., Feng J., Wang W., Deng Z., Zhang Y., Xiao L., Wang Z., Liu C.,
RA   Liu Q., Chen S., Wu M.;
RT   "The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma
RT   epigenetically.";
RL   Oncogene 39:3163-3178(2020).
RN   [68]
RP   STRUCTURE BY NMR OF 619-688 IN COMPLEX WITH ZINC IONS.
RX   PubMed=11226167; DOI=10.1093/emboj/20.1.165;
RA   Capili A.D., Schultz D.C., Rauscher F.J. III, Borden K.L.;
RT   "Solution structure of the PHD domain from the KAP-1 corepressor:
RT   structural determinants for PHD, RING and LIM zinc-binding domains.";
RL   EMBO J. 20:165-177(2001).
RN   [69]
RP   STRUCTURE BY NMR OF 624-812 OF WILD TYPE AND IN COMPLEX WITH UBE2I,
RP   SUMOYLATION AT LYS-676; LYS-750; LYS-779 AND LYS-804, AND MUTAGENESIS OF
RP   CYS-651; LEU-653; LEU-668 AND LEU-709.
RX   PubMed=18488044; DOI=10.1038/nsmb.1416;
RA   Zeng L., Yap K.L., Ivanov A.V., Wang X., Mujtaba S., Plotnikova O.,
RA   Rauscher F.J. III, Zhou M.M.;
RT   "Structural insights into human KAP1 PHD finger-bromodomain and its role in
RT   gene silencing.";
RL   Nat. Struct. Mol. Biol. 15:626-633(2008).
RN   [70]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 201-250.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of ms1043.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [71]
RP   VARIANT [LARGE SCALE ANALYSIS] MET-794.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Nuclear corepressor for KRAB domain-containing zinc finger
CC       proteins (KRAB-ZFPs). Mediates gene silencing by recruiting CHD3, a
CC       subunit of the nucleosome remodeling and deacetylation (NuRD) complex,
CC       and SETDB1 (which specifically methylates histone H3 at 'Lys-9'
CC       (H3K9me)) to the promoter regions of KRAB target genes. Enhances
CC       transcriptional repression by coordinating the increase in H3K9me, the
CC       decrease in histone H3 'Lys-9 and 'Lys-14' acetylation (H3K9ac and
CC       H3K14ac, respectively) and the disposition of HP1 proteins to silence
CC       gene expression. Recruitment of SETDB1 induces heterochromatinization.
CC       May play a role as a coactivator for CEBPB and NR3C1 in the
CC       transcriptional activation of ORM1. Also a corepressor for ERBB4.
CC       Inhibits E2F1 activity by stimulating E2F1-HDAC1 complex formation and
CC       inhibiting E2F1 acetylation. May serve as a partial backup to prevent
CC       E2F1-mediated apoptosis in the absence of RB1. Important regulator of
CC       CDKN1A/p21(CIP1). Has E3 SUMO-protein ligase activity toward itself via
CC       its PHD-type zinc finger. Also specifically sumoylates IRF7, thereby
CC       inhibiting its transactivation activity. Ubiquitinates p53/TP53 leading
CC       to its proteosomal degradation; the function is enhanced by MAGEC2 and
CC       MAGEA2, and possibly MAGEA3 and MAGEA6. Mediates the nuclear
CC       localization of KOX1, ZNF268 and ZNF300 transcription factors. In
CC       association with isoform 2 of ZFP90, is required for the
CC       transcriptional repressor activity of FOXP3 and the suppressive
CC       function of regulatory T-cells (Treg) (PubMed:23543754). Probably forms
CC       a corepressor complex required for activated KRAS-mediated promoter
CC       hypermethylation and transcriptional silencing of tumor suppressor
CC       genes (TSGs) or other tumor-related genes in colorectal cancer (CRC)
CC       cells (PubMed:24623306). Required to maintain a transcriptionally
CC       repressive state of genes in undifferentiated embryonic stem cells
CC       (ESCs) (PubMed:24623306). In ESCs, in collaboration with SETDB1, is
CC       also required for H3K9me3 and silencing of endogenous and introduced
CC       retroviruses in a DNA-methylation independent-pathway (By similarity).
CC       Associates at promoter regions of tumor suppressor genes (TSGs) leading
CC       to their gene silencing (PubMed:24623306). The SETDB1-TRIM28-ZNF274
CC       complex may play a role in recruiting ATRX to the 3'-exons of zinc-
CC       finger coding genes with atypical chromatin signatures to establish or
CC       maintain/protect H3K9me3 at these transcriptionally active regions
CC       (PubMed:27029610). {ECO:0000250|UniProtKB:Q62318,
CC       ECO:0000269|PubMed:10347202, ECO:0000269|PubMed:11959841,
CC       ECO:0000269|PubMed:15882967, ECO:0000269|PubMed:16107876,
CC       ECO:0000269|PubMed:16862143, ECO:0000269|PubMed:17079232,
CC       ECO:0000269|PubMed:17178852, ECO:0000269|PubMed:17704056,
CC       ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18060868,
CC       ECO:0000269|PubMed:18082607, ECO:0000269|PubMed:20424263,
CC       ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:20864041,
CC       ECO:0000269|PubMed:21940674, ECO:0000269|PubMed:23543754,
CC       ECO:0000269|PubMed:23665872, ECO:0000269|PubMed:24623306,
CC       ECO:0000269|PubMed:27029610, ECO:0000269|PubMed:8769649,
CC       ECO:0000269|PubMed:9016654}.
CC   -!- FUNCTION: (Microbial infection) Plays a critical role in the shutdown
CC       of lytic gene expression during the early stage of herpes virus 8
CC       primary infection. This inhibition is mediated through interaction with
CC       herpes virus 8 protein LANA1. {ECO:0000269|PubMed:24741090}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27;
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Interacts with SETX (PubMed:23149945). Oligomer; the RBCC
CC       domain homotrimerizes and interacts with one molecule of KRAB to form
CC       the KRAB-KAP1 corepressor complex. Binding to a KRAB domain is an
CC       absolute requirement for silencing gene expression. Interacts with
CC       CEBPB and NR3C1. Interacts with a number of KRAB-ZFP proteins including
CC       ZNF10, ZFP53, ZFP68, ZNF382 and ZNF256. Interacts with NCOR1, NR3C1 and
CC       CHD3. Interacts with CEBPB (via the RING-type and PHD-type zinc
CC       fingers). Component of a ternary complex that includes TRIM28, a HP1
CC       protein (CBX1, CBX3 OR CBX5), a KRAB domain-containing protein, and
CC       DNA. Interacts with CBX5 (via the PxVxL motif); the interaction occurs
CC       in interphase nuclei and competes for binding POGZ. Interacts with
CC       POGZ; the interaction competes for interaction with CBX5. Interacts
CC       with SETDB1; the interaction is enhanced by KAP1 sumoylation,
CC       stimulates SETDB1 histone methyltransferase activity and gene
CC       silencing. Interacts (via the PHD-type zinc finger) with UBE2I; the
CC       interaction is required for sumoylation and repressor activity.
CC       Component of the TRIM28/KAP1-ERBB4-MDM2 complex involved in connecting
CC       growth factor and DNA damage responses. Interacts directly with ERBB4;
CC       the interaction represses ERBB4-mediated transcription activity.
CC       Interacts with MDM2; the interaction contributes to p53/TP53
CC       inactivation. Component of the TRIM28/KAP1-MDM2-p53/TP53; involved in
CC       regulating p53/TP53 stabilization and activity. Interacts (via the
CC       leucine zipper alpha helical coiled-coil) with E2F1 (central region);
CC       the interaction inhibits E2F1 acetylation and transcriptional activity.
CC       Interacts with PPP1CA; the interaction dephosphorylates TRIM28 at Ser-
CC       824 and forms a complex at the p21 promoter site. Interacts with
CC       PPP1CB; the interaction is weak but is increased on dephosphorylation
CC       at Ser-824. Interacts with FES/FPS. Interacts with SMARCAD1. Interacts
CC       with, and sumoylates IRF7. Interacts with MAGEC2. Part of a complex
CC       composed of TRIM28, HDAC1, HDAC2 and EHMT2 (PubMed:21549307). Interacts
CC       with AICDA (By similarity). Interacts (via the RBCC domain) with KOX1
CC       (via the KRAB domain), ZNF268 (via the KRAB domain) and ZNF300 (via the
CC       KRAB domain); the interactions increase KOX1, ZNF268 and ZNF300 nuclear
CC       localization activities. The large PER complex involved in the histone
CC       methylation is composed of at least PER2, CBX3, TRIM28, SUV39H1 and/or
CC       SUV39H2; CBX3 mediates the formation of the complex. Interacts with
CC       isoform 2 of ZFP90. Forms a complex with FOXP3 in the presence of
CC       isoform 2 of ZFP90. Interacts with NR4A3; the interactions potentiates
CC       NR4A3 activity on NurRE promoter (By similarity). Interacts
CC       (unphosphorylated or phosphorylated form) with ZBTB1 (via BTB domain)
CC       (PubMed:24657165). Probably part of a corepressor complex containing
CC       ZNF304, TRIM28, SETDB1 and DNMT1 (PubMed:24623306). Interacts with
CC       ATRX. Forms a complex with ATRX, SETDB1 and ZNF274 (PubMed:27029610).
CC       Interacts with ZFP568; the interaction mediates ZFP568 transcriptional
CC       repression activity (By similarity). Interacts with RRP1B
CC       (PubMed:19710015). Interacts with CRY1 (By similarity). Interacts with
CC       ZNF263; recruited to the SIX3 promoter along with other proteins
CC       involved in chromatin modification and transcriptional corepression
CC       where it contributes to transcriptional repression (PubMed:32051553).
CC       Interacts with CYREN (via XLF motif) (By similarity). Interacts with
CC       TRIM17; this interaction prevents TRIM28 activity (PubMed:30042493).
CC       Interacts with ZNF746 (PubMed:31856708). {ECO:0000250|UniProtKB:Q62318,
CC       ECO:0000269|PubMed:10330177, ECO:0000269|PubMed:10347202,
CC       ECO:0000269|PubMed:11013263, ECO:0000269|PubMed:11226167,
CC       ECO:0000269|PubMed:11230151, ECO:0000269|PubMed:11959841,
CC       ECO:0000269|PubMed:15882967, ECO:0000269|PubMed:16107876,
CC       ECO:0000269|PubMed:16792528, ECO:0000269|PubMed:17056014,
CC       ECO:0000269|PubMed:17079232, ECO:0000269|PubMed:17512541,
CC       ECO:0000269|PubMed:17704056, ECO:0000269|PubMed:17942928,
CC       ECO:0000269|PubMed:18060868, ECO:0000269|PubMed:18082607,
CC       ECO:0000269|PubMed:18488044, ECO:0000269|PubMed:18675275,
CC       ECO:0000269|PubMed:19710015, ECO:0000269|PubMed:20424263,
CC       ECO:0000269|PubMed:20562864, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:20864041, ECO:0000269|PubMed:21549307,
CC       ECO:0000269|PubMed:21940674, ECO:0000269|PubMed:23149945,
CC       ECO:0000269|PubMed:23543754, ECO:0000269|PubMed:23665872,
CC       ECO:0000269|PubMed:24623306, ECO:0000269|PubMed:24657165,
CC       ECO:0000269|PubMed:27029610, ECO:0000269|PubMed:30042493,
CC       ECO:0000269|PubMed:31856708, ECO:0000269|PubMed:32051553,
CC       ECO:0000269|PubMed:9016654}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes virus 8 protein
CC       LANA1; this interaction facilitates establishment of viral latency.
CC       {ECO:0000269|PubMed:24741090}.
CC   -!- INTERACTION:
CC       Q13263; Q13185: CBX3; NbExp=4; IntAct=EBI-78139, EBI-78176;
CC       Q13263; P45973: CBX5; NbExp=11; IntAct=EBI-78139, EBI-78219;
CC       Q13263; Q12873: CHD3; NbExp=4; IntAct=EBI-78139, EBI-523590;
CC       Q13263; P43356: MAGEA2B; NbExp=6; IntAct=EBI-78139, EBI-5650739;
CC       Q13263; P43357: MAGEA3; NbExp=3; IntAct=EBI-78139, EBI-5651459;
CC       Q13263; P43360: MAGEA6; NbExp=2; IntAct=EBI-78139, EBI-1045155;
CC       Q13263; Q9UBF1: MAGEC2; NbExp=14; IntAct=EBI-78139, EBI-5651487;
CC       Q13263; Q9HCI5: MAGEE1; NbExp=2; IntAct=EBI-78139, EBI-949966;
CC       Q13263; O75376: NCOR1; NbExp=4; IntAct=EBI-78139, EBI-347233;
CC       Q13263; Q9BQF6: SENP7; NbExp=3; IntAct=EBI-78139, EBI-766251;
CC       Q13263; Q8TF47-3: ZFP90; NbExp=2; IntAct=EBI-78139, EBI-11419904;
CC       Q13263; P83917: Cbx1; Xeno; NbExp=2; IntAct=EBI-78139, EBI-78119;
CC       Q13263; P23198: Cbx3; Xeno; NbExp=2; IntAct=EBI-78139, EBI-78162;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10330177,
CC       ECO:0000269|PubMed:17178852, ECO:0000269|PubMed:20858735,
CC       ECO:0000269|PubMed:23665872, ECO:0000269|PubMed:24741090,
CC       ECO:0000269|PubMed:9016654}. Note=Associated with centromeric
CC       heterochromatin during cell differentiation through CBX1.
CC       {ECO:0000250|UniProtKB:Q62318}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13263-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13263-2; Sequence=VSP_010898;
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested including spleen,
CC       thymus, prostate, testis, ovary, small intestine, colon and peripheral
CC       blood leukocytes. {ECO:0000269|PubMed:9016654}.
CC   -!- DOMAIN: The HP1 box is both necessary and sufficient for HP1 binding.
CC       {ECO:0000269|PubMed:18082607}.
CC   -!- DOMAIN: The PHD-type zinc finger enhances CEBPB transcriptional
CC       activity. The PHD-type zinc finger, the HP1 box and the bromo domain,
CC       function together to assemble the machinery required for repression of
CC       KRAB domain-containing proteins. Acts as an intramolecular SUMO E3
CC       ligase for autosumoylation of bromodomain.
CC       {ECO:0000269|PubMed:18082607}.
CC   -!- DOMAIN: The RING-finger-B Box-coiled-coil/tripartite motif (RBCC/TRIM
CC       motif) is required for interaction with the KRAB domain of KRAB-zinc
CC       finger proteins. Binds four zinc ions per molecule. The RING finger and
CC       the N-terminal of the leucine zipper alpha helical coiled-coil region
CC       of RBCC are required for oligomerization.
CC       {ECO:0000269|PubMed:18082607}.
CC   -!- DOMAIN: Contains one Pro-Xaa-Val-Xaa-Leu (PxVxL) motif, which is
CC       required for interaction with chromoshadow domains. This motif requires
CC       additional residues -7, -6, +4 and +5 of the central Val which contact
CC       the chromoshadow domain. {ECO:0000269|PubMed:18082607}.
CC   -!- PTM: ATM-induced phosphorylation on Ser-824 represses sumoylation
CC       leading to the de-repression of expression of a subset of genes
CC       involved in cell cycle control and apoptosis in response to genotoxic
CC       stress. Dephosphorylation by the phosphatases, PPP1CA and PP1CB forms,
CC       allows sumoylation and expression of TRIM28 target genes.
CC       {ECO:0000269|PubMed:16862143, ECO:0000269|PubMed:17178852,
CC       ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:20424263}.
CC   -!- PTM: Sumoylation/desumoylation events regulate TRIM28-mediated
CC       transcriptional repression. Sumoylation is required for interaction
CC       with CHD3 and SETDB1 and the corepressor activity. Represses and is
CC       repressed by Ser-824 phosphorylation. Enhances the TRIM28 corepressor
CC       activity, inhibiting transcriptional activity of a number of genes
CC       including GADD45A and CDKN1A/p21. Lys-554, Lys-779 and Lys-804 are the
CC       major sites of sumoylation. In response to Dox-induced DNA damage,
CC       enhanced phosphorylation on Ser-824 prevents sumoylation and allows de-
CC       repression of CDKN1A/p21. {ECO:0000269|PubMed:16862143,
CC       ECO:0000269|PubMed:17079232, ECO:0000269|PubMed:17178852,
CC       ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18488044,
CC       ECO:0000269|PubMed:20388717, ECO:0000269|PubMed:20424263}.
CC   -!- PTM: Auto-ubiquitinated; enhanced by MAGEA2 and MAGEC2.
CC       {ECO:0000269|PubMed:20864041}.
CC   -!- PTM: Citrullinated by PADI4. {ECO:0000250|UniProtKB:Q62318}.
CC   -!- PTM: ADP-ribosylated by SIRT6, promoting TRIM28/KAP1 interaction with
CC       CBX5, thereby contributing to the packaging of LINE-1 retrotransposon
CC       elements into transcriptionally repressive heterochromatin.
CC       {ECO:0000250|UniProtKB:Q62318}.
CC   -!- SIMILARITY: Belongs to the TRIM/RBCC family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U78773; AAB37341.1; -; mRNA.
DR   EMBL; X97548; CAA66150.1; -; mRNA.
DR   EMBL; U95040; AAB51517.1; -; mRNA.
DR   EMBL; BC004978; AAH04978.1; -; mRNA.
DR   EMBL; BC007390; AAH07390.2; -; mRNA.
DR   EMBL; BC052986; AAH52986.1; -; mRNA.
DR   EMBL; U31657; AAA74954.1; -; mRNA.
DR   CCDS; CCDS12985.1; -. [Q13263-1]
DR   PIR; G01950; G01950.
DR   RefSeq; NP_005753.1; NM_005762.2. [Q13263-1]
DR   PDB; 1FP0; NMR; -; A=619-679.
DR   PDB; 2RO1; NMR; -; A=624-812.
DR   PDB; 2YVR; X-ray; 1.80 A; A/B=201-250.
DR   PDB; 6H3A; X-ray; 5.50 A; A/F=53-434.
DR   PDB; 6I9H; NMR; -; A=54-145.
DR   PDB; 6QAJ; X-ray; 2.90 A; A/B=56-413.
DR   PDB; 6QU1; X-ray; 3.70 A; A=53-434.
DR   PDBsum; 1FP0; -.
DR   PDBsum; 2RO1; -.
DR   PDBsum; 2YVR; -.
DR   PDBsum; 6H3A; -.
DR   PDBsum; 6I9H; -.
DR   PDBsum; 6QAJ; -.
DR   PDBsum; 6QU1; -.
DR   AlphaFoldDB; Q13263; -.
DR   BMRB; Q13263; -.
DR   SASBDB; Q13263; -.
DR   SMR; Q13263; -.
DR   BioGRID; 115457; 1288.
DR   CORUM; Q13263; -.
DR   DIP; DIP-30891N; -.
DR   ELM; Q13263; -.
DR   IntAct; Q13263; 186.
DR   MINT; Q13263; -.
DR   STRING; 9606.ENSP00000253024; -.
DR   ChEMBL; CHEMBL3769297; -.
DR   GlyGen; Q13263; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13263; -.
DR   MetOSite; Q13263; -.
DR   PhosphoSitePlus; Q13263; -.
DR   SwissPalm; Q13263; -.
DR   BioMuta; TRIM28; -.
DR   DMDM; 3183179; -.
DR   CPTAC; CPTAC-446; -.
DR   CPTAC; CPTAC-447; -.
DR   EPD; Q13263; -.
DR   jPOST; Q13263; -.
DR   MassIVE; Q13263; -.
DR   MaxQB; Q13263; -.
DR   PaxDb; Q13263; -.
DR   PeptideAtlas; Q13263; -.
DR   PRIDE; Q13263; -.
DR   ProteomicsDB; 59266; -. [Q13263-1]
DR   ProteomicsDB; 59267; -. [Q13263-2]
DR   ABCD; Q13263; 2 sequenced antibodies.
DR   Antibodypedia; 4109; 805 antibodies from 48 providers.
DR   DNASU; 10155; -.
DR   Ensembl; ENST00000253024.10; ENSP00000253024.4; ENSG00000130726.12. [Q13263-1]
DR   Ensembl; ENST00000341753.10; ENSP00000342232.5; ENSG00000130726.12. [Q13263-2]
DR   GeneID; 10155; -.
DR   KEGG; hsa:10155; -.
DR   MANE-Select; ENST00000253024.10; ENSP00000253024.4; NM_005762.3; NP_005753.1.
DR   UCSC; uc002qtg.2; human. [Q13263-1]
DR   CTD; 10155; -.
DR   DisGeNET; 10155; -.
DR   GeneCards; TRIM28; -.
DR   HGNC; HGNC:16384; TRIM28.
DR   HPA; ENSG00000130726; Low tissue specificity.
DR   MalaCards; TRIM28; -.
DR   MIM; 601742; gene.
DR   neXtProt; NX_Q13263; -.
DR   OpenTargets; ENSG00000130726; -.
DR   Orphanet; 654; Nephroblastoma.
DR   PharmGKB; PA38131; -.
DR   VEuPathDB; HostDB:ENSG00000130726; -.
DR   eggNOG; KOG2177; Eukaryota.
DR   GeneTree; ENSGT00940000160527; -.
DR   HOGENOM; CLU_005817_2_0_1; -.
DR   InParanoid; Q13263; -.
DR   OMA; DCKDEVP; -.
DR   OrthoDB; 756911at2759; -.
DR   PhylomeDB; Q13263; -.
DR   TreeFam; TF106455; -.
DR   PathwayCommons; Q13263; -.
DR   Reactome; R-HSA-212436; Generic Transcription Pathway.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-9609690; HCMV Early Events.
DR   SignaLink; Q13263; -.
DR   SIGNOR; Q13263; -.
DR   UniPathway; UPA00886; -.
DR   BioGRID-ORCS; 10155; 166 hits in 1153 CRISPR screens.
DR   ChiTaRS; TRIM28; human.
DR   EvolutionaryTrace; Q13263; -.
DR   GeneWiki; TRIM28; -.
DR   GenomeRNAi; 10155; -.
DR   Pharos; Q13263; Tbio.
DR   PRO; PR:Q13263; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q13263; protein.
DR   Bgee; ENSG00000130726; Expressed in left testis and 100 other tissues.
DR   ExpressionAtlas; Q13263; baseline and differential.
DR   Genevisible; Q13263; HS.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0000791; C:euchromatin; IEA:Ensembl.
DR   GO; GO:0000792; C:heterochromatin; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; ISS:BHF-UCL.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0070087; F:chromo shadow domain binding; IPI:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0035851; F:Krueppel-associated box domain binding; IDA:UniProtKB.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IEA:Ensembl.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0019789; F:SUMO transferase activity; EXP:Reactome.
DR   GO; GO:0003713; F:transcription coactivator activity; ISS:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006325; P:chromatin organization; IEA:UniProtKB-KW.
DR   GO; GO:0060028; P:convergent extension involved in axis elongation; IEA:Ensembl.
DR   GO; GO:0043045; P:DNA methylation involved in embryo development; IEA:Ensembl.
DR   GO; GO:0006281; P:DNA repair; IDA:UniProtKB.
DR   GO; GO:0007566; P:embryo implantation; IEA:Ensembl.
DR   GO; GO:0060669; P:embryonic placenta morphogenesis; IEA:Ensembl.
DR   GO; GO:0001837; P:epithelial to mesenchymal transition; ISS:HGNC-UCL.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:1901536; P:negative regulation of DNA demethylation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:0045869; P:negative regulation of single stranded viral RNA replication via double stranded DNA intermediate; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0043388; P:positive regulation of DNA binding; IEA:Ensembl.
DR   GO; GO:0090309; P:positive regulation of DNA methylation-dependent heterochromatin assembly; IMP:UniProtKB.
DR   GO; GO:0045739; P:positive regulation of DNA repair; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; ISS:HGNC-UCL.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IDA:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0016925; P:protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; IMP:UniProtKB.
DR   GO; GO:2000653; P:regulation of genetic imprinting; IEA:Ensembl.
DR   GO; GO:0044790; P:suppression of viral release by host; IDA:UniProtKB.
DR   CDD; cd16765; RING-HC_TIF1beta; 1.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR037373; KAP1.
DR   InterPro; IPR042713; TIF1beta_RING-HC.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR25462:SF274; PTHR25462:SF274; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 2.
DR   Pfam; PF14634; zf-RING_5; 1.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 2.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ADP-ribosylation; Alternative splicing;
KW   Chromatin regulator; Citrullination; Coiled coil;
KW   Direct protein sequencing; Host-virus interaction; Isopeptide bond;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Repressor; Transcription; Transcription regulation; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.5, ECO:0000269|Ref.6,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   CHAIN           2..835
FT                   /note="Transcription intermediary factor 1-beta"
FT                   /id="PRO_0000056392"
FT   DOMAIN          697..801
FT                   /note="Bromo"
FT   ZN_FING         65..121
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         148..195
FT                   /note="B box-type 1; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         204..245
FT                   /note="B box-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         625..672
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          1..49
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          65..376
FT                   /note="RBCC domain"
FT   REGION          246..376
FT                   /note="Leucine zipper alpha helical coiled-coil region"
FT   REGION          247..376
FT                   /note="Interaction with MAGEC2"
FT   REGION          366..370
FT                   /note="Involved in binding PPP1CA"
FT   REGION          411..480
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          476..513
FT                   /note="HP1 box"
FT   REGION          584..618
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          815..835
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           481..494
FT                   /note="PxVxL motif"
FT   BINDING         153
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         156
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         177
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         181
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         209
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         212
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         232
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         237
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.5, ECO:0000269|Ref.6,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         19
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         50
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         138
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         266
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         304
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         340
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         377
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         417
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         437
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         439
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         453
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         470
FT                   /note="Citrulline"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         471
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         472
FT                   /note="Citrulline"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         473
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:17081983, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         479
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         489
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         498
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         501
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         541
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         594
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         683
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         689
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         697
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         752
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         755
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         757
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         770
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         774
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         779
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q62318"
FT   MOD_RES         784
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         824
FT                   /note="Phosphoserine; by ATM and ATR and dsDNA kinase"
FT                   /evidence="ECO:0000269|PubMed:16862143,
FT                   ECO:0000269|PubMed:17178852, ECO:0000269|PubMed:17942393,
FT                   ECO:0000269|PubMed:20424263"
FT   CROSSLNK        31
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        127
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        199
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        254
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        261
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        272
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        304
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        319
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        366
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        377
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        377
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25755297, ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        407
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        434
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        469
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        469
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        507
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        554
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:17079232"
FT   CROSSLNK        554
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        575
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        676
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000269|PubMed:18488044"
FT   CROSSLNK        750
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:18082607"
FT   CROSSLNK        750
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        750
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        770
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        774
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        779
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        779
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        804
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO); alternate"
FT                   /evidence="ECO:0000269|PubMed:17079232"
FT   CROSSLNK        804
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         114..195
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010898"
FT   VARIANT         794
FT                   /note="T -> M (in dbSNP:rs56229738)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042386"
FT   MUTAGEN         65
FT                   /note="C->A: Reduces nuclear localization activity of
FT                   ZNF268; when associated with A-68."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         68
FT                   /note="C->A: Reduces nuclear localization activity of
FT                   ZNF268; when associated with A-65."
FT                   /evidence="ECO:0000269|PubMed:23665872"
FT   MUTAGEN         306
FT                   /note="L->P: Disrupts the interaction with ZNF350 and amost
FT                   completely relieves the transcription repressive effect of
FT                   sumoylated TRIM28."
FT                   /evidence="ECO:0000269|PubMed:17942393"
FT   MUTAGEN         366
FT                   /note="K->G: Greatly reduced interaction with PPP1CA."
FT                   /evidence="ECO:0000269|PubMed:20424263"
FT   MUTAGEN         368
FT                   /note="I->G: Increased interaction with PPP1CA. Greatly
FT                   decreased phosphorylation on S-824."
FT                   /evidence="ECO:0000269|PubMed:20424263"
FT   MUTAGEN         370
FT                   /note="F->A: Some reduction in interaction with PPP1CA."
FT                   /evidence="ECO:0000269|PubMed:20424263"
FT   MUTAGEN         370
FT                   /note="F->G: Some reduction in interaction with PPP1CA."
FT                   /evidence="ECO:0000269|PubMed:20424263"
FT   MUTAGEN         440
FT                   /note="S->A: No effect on interaction with PPP1CA nor on
FT                   sumoylation levels. Decreased sumoylation levels; when
FT                   associated with D-501 and D-824."
FT                   /evidence="ECO:0000269|PubMed:20424263"
FT   MUTAGEN         488
FT                   /note="V->E: Abolishes interaction with CBX5; when
FT                   associated with E-490."
FT                   /evidence="ECO:0000269|PubMed:20562864"
FT   MUTAGEN         490
FT                   /note="L->E: Abolishes interaction with CBX5; when
FT                   associated with E-488."
FT                   /evidence="ECO:0000269|PubMed:20562864"
FT   MUTAGEN         501
FT                   /note="S->A: No effect on interaction with PPP1CA nor on
FT                   sumoylation levels. Decreased sumoylation levels; when
FT                   associated with D-440 and D-824."
FT                   /evidence="ECO:0000269|PubMed:20424263"
FT   MUTAGEN         554
FT                   /note="K->R: Moderately reduces sumoylation and repression.
FT                   Abolishes both sumoylation and repression; when associated
FT                   with R-575. Relieves the repressor activity on Dox-induced
FT                   GADD45A transcription and 2-fold increase in
FT                   phosphorylation at Ser-824; when associated with R-779 and
FT                   R-804."
FT                   /evidence="ECO:0000269|PubMed:17079232,
FT                   ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18082607"
FT   MUTAGEN         575
FT                   /note="K->R: Modestly reduced sumoylation and repression.
FT                   Abolishes both sumoylation and repression; when associated
FT                   with R-554."
FT                   /evidence="ECO:0000269|PubMed:17079232,
FT                   ECO:0000269|PubMed:18082607"
FT   MUTAGEN         651
FT                   /note="C->A: Complete loss of the PHD finger-mediated
FT                   stimulatory effect on sumoylation. Loss of binding UBE2I."
FT                   /evidence="ECO:0000269|PubMed:18082607,
FT                   ECO:0000269|PubMed:18488044"
FT   MUTAGEN         653
FT                   /note="L->A: Greatly reduced sumoylation. Little further
FT                   effect on sumoylation; when associated with A-668 and/or
FT                   A-709."
FT                   /evidence="ECO:0000269|PubMed:18488044"
FT   MUTAGEN         668
FT                   /note="L->A: Little effect on sumoylation. Little further
FT                   effect on sumoylation; when associated with A-653 and/or
FT                   A-709."
FT                   /evidence="ECO:0000269|PubMed:18488044"
FT   MUTAGEN         676
FT                   /note="K->R: Modestly reduces sumoylation and repression."
FT                   /evidence="ECO:0000269|PubMed:17079232,
FT                   ECO:0000269|PubMed:18082607"
FT   MUTAGEN         709
FT                   /note="L->A: Greatly reduced sumoylation. Little further
FT                   effect on sumoylation; when associated with A-653 and/or
FT                   A-668."
FT                   /evidence="ECO:0000269|PubMed:18488044"
FT   MUTAGEN         750
FT                   /note="K->R: Some reduced sumoylation and repression."
FT                   /evidence="ECO:0000269|PubMed:18082607"
FT   MUTAGEN         779
FT                   /note="K->R: Abolishes both sumoylation and repression;
FT                   when associated with R-804. Relieves the repressor activity
FT                   on Dox-induced GADD45A transcription and 2-fold increase in
FT                   phosphorylation at Ser-824; when associated with R-554 and
FT                   R-804."
FT                   /evidence="ECO:0000269|PubMed:17079232,
FT                   ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18082607"
FT   MUTAGEN         804
FT                   /note="K->R: Abolishes both sumoylation and repression;
FT                   when associated with R-779. Relieves the repressor activity
FT                   on Dox-induced GADD45A transcription and 2-fold increase in
FT                   phosphorylation at Ser-824; when associated with R-554 and
FT                   R-779."
FT                   /evidence="ECO:0000269|PubMed:17079232,
FT                   ECO:0000269|PubMed:17942393, ECO:0000269|PubMed:18082607"
FT   MUTAGEN         824
FT                   /note="S->A: Suppresses Dox-induced CDKN1A/p21 promoter
FT                   activation. No effect on sumoylation levels. Decreased
FT                   sumoylation levels; when associated with D-440 and D-501."
FT                   /evidence="ECO:0000269|PubMed:17942393,
FT                   ECO:0000269|PubMed:20424263"
FT   MUTAGEN         824
FT                   /note="S->D: Enhances Dox-induced CDKN1A/p21 promoter
FT                   activation. Decreased sumoylation with or without
FT                   Dox-treatment."
FT                   /evidence="ECO:0000269|PubMed:17942393,
FT                   ECO:0000269|PubMed:20424263"
FT   CONFLICT        162
FT                   /note="A -> G (in Ref. 1; AAB37341)"
FT                   /evidence="ECO:0000305"
FT   HELIX           56..60
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   HELIX           61..63
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   TURN            66..68
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   STRAND          74..76
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   STRAND          78..80
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   STRAND          86..92
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   STRAND          105..107
FT                   /evidence="ECO:0007829|PDB:6I9H"
FT   STRAND          113..116
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   TURN            118..120
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   STRAND          123..125
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   TURN            126..128
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   STRAND          138..140
FT                   /evidence="ECO:0007829|PDB:6I9H"
FT   STRAND          210..212
FT                   /evidence="ECO:0007829|PDB:2YVR"
FT   STRAND          219..221
FT                   /evidence="ECO:0007829|PDB:2YVR"
FT   TURN            222..225
FT                   /evidence="ECO:0007829|PDB:2YVR"
FT   STRAND          226..228
FT                   /evidence="ECO:0007829|PDB:2YVR"
FT   HELIX           230..234
FT                   /evidence="ECO:0007829|PDB:2YVR"
FT   TURN            235..239
FT                   /evidence="ECO:0007829|PDB:2YVR"
FT   STRAND          242..244
FT                   /evidence="ECO:0007829|PDB:2YVR"
FT   HELIX           245..349
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   HELIX           350..353
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   HELIX           358..361
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   HELIX           362..369
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   HELIX           390..397
FT                   /evidence="ECO:0007829|PDB:6QAJ"
FT   STRAND          620..626
FT                   /evidence="ECO:0007829|PDB:1FP0"
FT   STRAND          629..631
FT                   /evidence="ECO:0007829|PDB:1FP0"
FT   STRAND          633..635
FT                   /evidence="ECO:0007829|PDB:1FP0"
FT   TURN            641..643
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   STRAND          651..653
FT                   /evidence="ECO:0007829|PDB:1FP0"
FT   STRAND          661..663
FT                   /evidence="ECO:0007829|PDB:1FP0"
FT   TURN            666..669
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   STRAND          684..690
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   HELIX           698..713
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   HELIX           717..721
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   STRAND          730..732
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   HELIX           740..748
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   STRAND          750..753
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   HELIX           758..775
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   HELIX           783..799
FT                   /evidence="ECO:0007829|PDB:2RO1"
FT   TURN            800..802
FT                   /evidence="ECO:0007829|PDB:2RO1"
SQ   SEQUENCE   835 AA;  88550 MW;  2027BABB7C94FE20 CRC64;
     MAASAAAASA AAASAASGSP GPGEGSAGGE KRSTAPSAAA SASASAAASS PAGGGAEALE
     LLEHCGVCRE RLRPEREPRL LPCLHSACSA CLGPAAPAAA NSSGDGGAAG DGTVVDCPVC
     KQQCFSKDIV ENYFMRDSGS KAATDAQDAN QCCTSCEDNA PATSYCVECS EPLCETCVEA
     HQRVKYTKDH TVRSTGPAKS RDGERTVYCN VHKHEPLVLF CESCDTLTCR DCQLNAHKDH
     QYQFLEDAVR NQRKLLASLV KRLGDKHATL QKSTKEVRSS IRQVSDVQKR VQVDVKMAIL
     QIMKELNKRG RVLVNDAQKV TEGQQERLER QHWTMTKIQK HQEHILRFAS WALESDNNTA
     LLLSKKLIYF QLHRALKMIV DPVEPHGEMK FQWDLNAWTK SAEAFGKIVA ERPGTNSTGP
     APMAPPRAPG PLSKQGSGSS QPMEVQEGYG FGSGDDPYSS AEPHVSGVKR SRSGEGEVSG
     LMRKVPRVSL ERLDLDLTAD SQPPVFKVFP GSTTEDYNLI VIERGAAAAA TGQPGTAPAG
     TPGAPPLAGM AIVKEEETEA AIGAPPTATE GPETKPVLMA LAEGPGAEGP RLASPSGSTS
     SGLEVVAPEG TSAPGGGPGT LDDSATICRV CQKPGDLVMC NQCEFCFHLD CHLPALQDVP
     GEEWSCSLCH VLPDLKEEDG SLSLDGADST GVVAKLSPAN QRKCERVLLA LFCHEPCRPL
     HQLATDSTFS LDQPGGTLDL TLIRARLQEK LSPPYSSPQE FAQDVGRMFK QFNKLTEDKA
     DVQSIIGLQR FFETRMNEAF GDTKFSAVLV EPPPMSLPGA GLSSQELSGG PGDGP
//
